Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Master Trader who wrote (51156)	2/3/1999 11:42:00 AM
From: StalkFunder	Read Replies (2) \| Respond to of 119973

IONS picks before the bell... Sorry folks, I was asleep... he sure had some winners today... FONX GENZL PGNX OMKT Applied Cellular <ACTC.O> plans Inteletek IPO PALM BEACH, Fla., Feb 3 (Reuters) - Communications systems provider Applied Cellular Technology, Inc. on Wednesday said its board approved a company restructuring, including the spin-off of Inteletek, Inc., its computer group. FONX fonx news not on dow wire Fonix Corporation, the innovation leader in human-computer interaction technology, today announced that the Inferno venture of Lucent Technologies (NYSE: LU) will offer Fonix's Allegro handwriting recognition capabilities as part of its Inferno(TM) operating system. PGNX) today announced its discovery of an anti-CCR5 monoclonal antibody that potently blocks HIV replication in the laboratory. In a separate development, Progenics described the completion and preliminary findings of its Phase I/II clinical trial of PRO 542 in HIV positive adults. The results were reported today in separate presentations at the 6th Conference on Retroviruses and Opportunistic Infections. Open Market <OMKT.O>, Lycos <LCOS.O> in pact Open Market Inc. an Internet commerce software company said Wednesday that it has an agreement to integrate its software into Lycos Inc.'s e-commerce infrastructure. The revenue-sharing agreement calls for installation of Open Market's Transact software to power Lycos' electronic marketplace and distribution of Open Market's ShopSite store-building software to enable the development of a seamlessly integrated community of retailers and suppliers. GENZL Orthopedic surgeons reported that 85 percent of patients treated with Genzyme Tissue Repair's (Nasdaq: GENZL) Carticel(TM) autologous cultured chondrocytes to repair damaged cartilage on the thigh-bone part of the knee showed improvement in four key measures three years after therapy. This result is revealed in the fifth report of the company's Cartilage Repair Registry, which chronicles the progress of patients treated with Carticel, a treatment that employs a proprietary process to grow a patient's own cartilage to repair certain types of knee cartilage damage. Previous reports of the registry had shown improvement at two years after surgery. The fifth report is the first to include data from patients three years after surgery.